Literature DB >> 16449633

The retinoblastoma protein is required for Ras-induced oncogenic transformation.

Jonathan P Williams1, Timothy Stewart, Bihua Li, Roseann Mulloy, Dessislava Dimova, Marie Classon.   

Abstract

Most human cancers involve either mutational activation of the Ras oncogenic pathway and/or inactivation of the retinoblastoma tumor suppressor (RB) pathway. Paradoxically, tumors that harbor Ras mutations almost invariably retain expression of a wild-type pRB protein. We explain this phenomenon by demonstrating that Ras-induced oncogenic transformation surprisingly depends on functional pRB protein. Cells lacking pRB are less susceptible to the oncogenic actions of H-RasV12 than wild-type cells and activated Ras has an inhibitory effect on the proliferation of pRB-deficient human tumor cells. In addition, depletion of pRB from Ras-transformed murine cells or human tumor cells that harbor Ras pathway mutations inhibits their proliferation and anchorage-independent growth. In sharp contrast to pRB-/- 3T3 cells, fibroblasts deficient in other pRB family members (p107 and p130) are more susceptible to Ras-mediated transformation than wild-type 3T3 cells. Moreover, loss of pRB in tumor cells harboring a Ras mutation results in increased expression of p107, and overexpression of p107 but not pRB strongly inhibits proliferation of these tumor cells. Together, these findings suggest that pRB and p107 have distinct roles in Ras-mediated transformation and suggest a novel tumor-suppressive role for p107 in the context of activated Ras.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449633      PMCID: PMC1367176          DOI: 10.1128/MCB.26.4.1170-1182.2006

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  76 in total

1.  Identification of a growth suppression domain within the retinoblastoma gene product.

Authors:  X Q Qin; T Chittenden; D M Livingston; W G Kaelin
Journal:  Genes Dev       Date:  1992-06       Impact factor: 11.361

2.  Abundance and state of phosphorylation of the retinoblastoma susceptibility gene product in human colon cancer.

Authors:  R Gope; M L Gope
Journal:  Mol Cell Biochem       Date:  1992-03-25       Impact factor: 3.396

3.  Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.

Authors:  L Zhu; S van den Heuvel; K Helin; A Fattaey; M Ewen; D Livingston; N Dyson; E Harlow
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

4.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.

Authors:  J M Horowitz; S H Park; E Bogenmann; J C Cheng; D W Yandell; F J Kaye; J D Minna; T P Dryja; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

Review 5.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

6.  Induction of cyclin D1 overexpression by activated ras.

Authors:  J Filmus; A I Robles; W Shi; M J Wong; L L Colombo; C J Conti
Journal:  Oncogene       Date:  1994-12       Impact factor: 9.867

7.  A cell cycle regulator potentially involved in genesis of many tumor types.

Authors:  A Kamb; N A Gruis; J Weaver-Feldhaus; Q Liu; K Harshman; S V Tavtigian; E Stockert; R S Day; B E Johnson; M H Skolnick
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

8.  Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression.

Authors:  H J Xu; P Cairns; S X Hu; M A Knowles; W F Benedict
Journal:  Int J Cancer       Date:  1993-03-12       Impact factor: 7.396

9.  Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.

Authors:  T Kashii; Y Mizushima; S Monno; K Nakagawa; M Kobayashi
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.

Authors:  K Münger; B A Werness; N Dyson; W C Phelps; E Harlow; P M Howley
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

View more
  27 in total

Review 1.  Surprising dependency for retinoblastoma protein in ras-mediated tumorigenesis.

Authors:  James DeGregori
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

2.  Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.

Authors:  Jayasree S Nair; Alan L Ho; Archie N Tse; Jesse Coward; Haider Cheema; Grazia Ambrosini; Nicholas Keen; Gary K Schwartz
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

3.  E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8.

Authors:  Erick J Morris; Jun-Yuan Ji; Fajun Yang; Luisa Di Stefano; Anabel Herr; Nam-Sung Moon; Eun-Jeong Kwon; Kevin M Haigis; Anders M Näär; Nicholas J Dyson
Journal:  Nature       Date:  2008-09-14       Impact factor: 49.962

4.  Distinct roles for p107 and p130 in Rb-independent cellular senescence.

Authors:  Brian D Lehmann; Adam M Brooks; Matthew S Paine; William H Chappell; James A McCubrey; David M Terrian
Journal:  Cell Cycle       Date:  2008-03-07       Impact factor: 4.534

5.  Visualizing dynamic E2F-mediated repression in vivo.

Authors:  Monica Agromayor; Elzbieta Wloga; Benedetta Naglieri; John Abrashkin; Kapil Verma; Lili Yamasaki
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

6.  Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function.

Authors:  James I Macdonald; Frederick A Dick
Journal:  Genes Cancer       Date:  2012-11

7.  Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas.

Authors:  Manish K Gala; Yusuke Mizukami; Long P Le; Kentaro Moriichi; Thomas Austin; Masayoshi Yamamoto; Gregory Y Lauwers; Nabeel Bardeesy; Daniel C Chung
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

Review 8.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

9.  A dual role for the dREAM/MMB complex in the regulation of differentiation-specific E2F/RB target genes.

Authors:  Hangnoh Lee; Linda Ragusano; Ana Martinez; Jagdip Gill; Dessislava K Dimova
Journal:  Mol Cell Biol       Date:  2012-03-26       Impact factor: 4.272

10.  Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras.

Authors:  Yoonsoo Park; Akihito Kubo; Takefumi Komiya; Amy Coxon; Kristin Beebe; Len Neckers; Paul S Meltzer; Frederic J Kaye
Journal:  Cell Cycle       Date:  2008-05-30       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.